Nimodipine is given in:
**Core Concept**
Nimodipine is a calcium channel blocker, specifically a dihydropyridine derivative, that selectively targets L-type calcium channels in the cerebrovascular smooth muscle. This action results in vasodilation and improved blood flow to the brain, particularly beneficial in cases of subarachnoid hemorrhage.
**Why the Correct Answer is Right**
Nimodipine primarily crosses the blood-brain barrier due to its lipophilic properties, allowing it to exert its effects directly on cerebral vessels. By inhibiting L-type calcium channels, nimodipine reduces cerebral vasoconstriction and subsequent ischemia, thereby improving outcomes in patients with subarachnoid hemorrhage. This is particularly important in the context of aneurysmal rupture, where nimodipine's neuroprotective effects can help mitigate the risk of delayed cerebral ischemia.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is likely incorrect as nimodipine's primary indication is not related to peripheral vascular disease or hypertension management.
**Option B:** This option may be incorrect as nimodipine is not typically used for the treatment of acute myocardial infarction or angina pectoris.
**Option C:** This option is likely incorrect as nimodipine's mechanism of action is not primarily related to bronchodilation or the treatment of asthma.
**Clinical Pearl / High-Yield Fact**
Nimodipine's selective action on L-type calcium channels in the cerebrovascular smooth muscle makes it an effective adjunctive treatment in the management of subarachnoid hemorrhage, particularly when used in conjunction with other neuroprotective strategies.
**Correct Answer:** C. Subarachnoid hemorrhage